Chapter review

Fitzgerald PMHNP board review. ch10. Schizophrenia. This is drive 4 of 6. When I say Pause. Answer. wait, then I will give the answer. New section. Clozapine, LAIs, and treatment-resistance rules. Topic. Treatment resistance definition. Bottom Line Summary. * **Treatment resistance definition**: Treatment-resistant schizophrenia is defined as little or no symptomatic response following at least two adequate trials of different antipsychotics at therapeutic dose ranges for at least 6 weeks each. * **Clozapine indication**: **Clozapine** is the gold-standard third-line agent for treatment-resistant schizophrenia, persistent suicide attempt risk, or chronic aggressive behavior. * **Absolute Neutrophil Count (ANC) criteria**: Baseline ANC must be at least 1500 / mm3 (or at least 1000 / mm3 for benign ethnic neutropenia) before starting **clozapine**. Interrupt treatment if ANC drops below 1000 / mm3. * **Clozapine monitoring schedule**: Monitor ANC weekly for the first 6 months, biweekly for months 6 through 12, and monthly thereafter for the duration of therapy. * **Smoking interaction via CYP1A2**: Polycyclic aromatic hydrocarbons in tobacco smoke induce **CYP1A2**, accelerating **clozapine** and **olanzapine** metabolism and lowering blood levels. Smoking cessation increases drug levels, raising toxicity risk. * **Long-acting injectables (LAIs)**: **LAIs** are the primary strategy for nonadherence. Options include **paliperidone palmitate** given monthly, every 3 months, or every 6 months, as well as **haloperidol decanoate** and **fluphenazine decanoate**. * **Neuroleptic Malignant Syndrome (NMS) marker**: NMS presents with muscle rigidity, hyperthermia, altered mental status, and autonomic instability. Elevated serum **creatine kinase (CK)** above 1000 IU/L correlates with rigidity severity. High-Yield Concept Review: Treatment Resistance, Clozapine, and LAIs. Treatment Resistance Definition and Clinical Rules. Treatment-resistant schizophrenia occurs when a patient fails to show adequate symptomatic improvement after two or more trials of different antipsychotics. Each trial must be administered at a therapeutic dose range for a minimum duration of 6 weeks. Before declaring true treatment resistance, the clinician must confirm medication adherence, rule out active substance use disorder, and exclude underlying medical causes or drug interactions. **First-line** therapy for acute schizophrenia consists of second-generation antipsychotics (SGAs) such as **risperidone**, **olanzapine**, **quetiapine**, **aripiprazole**, or **ziprasidone** due to lower extrapyramidal symptom (EPS) and tardive dyskinesia risks compared to first-generation antipsychotics (FGAs). **Board trap**: Assuming a patient is treatment-resistant when the true issue is covert nonadherence. Up to 20% of inpatient and 50% of outpatient individuals fail to take oral psychotropics as prescribed. Always evaluate adherence or switch to a long-acting injectable before labeling an illness as treatment-resistant. Clozapine Protocols and Safety Rules. **Clozapine** is a second-generation antipsychotic indicated specifically for treatment-resistant schizophrenia, severe persistent suicidality, or chronic violence. Although highly effective for positive and negative symptoms, it is classified as a third-line option due to significant adverse effect risks. **Safety alert**: **Clozapine** carries a risk of life-threatening agranulocytosis in 1% to 2% of patients. Absolute Neutrophil Count (ANC) monitoring is mandatory. Baseline ANC must be at least 1500 / mm3 in the general population or at least 1000 / mm3 in individuals with documented benign ethnic neutropenia (BEN). The monitoring schedule requires weekly ANC checks for the first 6 months, biweekly checks for months 6 to 12, and monthly checks thereafter. If ANC falls below 1000 / mm3, **clozapine** treatment must be interrupted immediately. **Board trap**: Confusing total white blood cell (WBC) count with ANC. National guidelines mandate monitoring ANC exclusively, as ANC isolates mature fighting neutrophils from total leukocyte counts. Additional high-yield **clozapine** pearls: * **Gastrointestinal hypomotility**: Severe constipation can progress to paralytic ileus or small bowel obstruction. Every patient on **clozapine** should be placed on a prophylactic bowel regimen such as docusate or polyethylene glycol. * **CYP1A2 induction by tobacco**: Hydrocarbons in cigarette smoke induce **CYP1A2**, increasing **clozapine** breakdown and lowering plasma levels. Patients who smoke require higher doses. Hospitalization or smoking cessation removes the inducer, leading to rapid clozapine accumulation, extreme sedation, seizures, or toxicity. * **Metabolic and neurological risks**: **Clozapine** carries high risks for weight gain, dyslipidemia, new-onset diabetes, dose-dependent seizures, myocarditis, orthostatic hypotension, and severe sialorrhea (drooling). Long-Acting Injectables (LAIs). LAIs are indicated for patients with partial or complete nonadherence to oral antipsychotics. Switching to an LAI reduces relapse rates, lowers rehospitalization, and stabilizes plasma drug levels. * **First-generation LAIs**: **Haloperidol decanoate** and **fluphenazine decanoate** are administered intramuscularly every 2 to 4 weeks. They carry higher risks for EPS and tardive dyskinesia. * **Second-generation LAIs**: **Paliperidone palmitate** offers flexible dosing intervals, including monthly formulations, a 3-month formulation, and a 6-month formulation. **Risperidone** LAI and **aripiprazole** LAI are also widely utilized options. **First-line** strategy for nonadherent patients experiencing recurrent relapses is transitioning from oral SGAs to an SGA LAI formulation once oral tolerability is established. Fitzgerald Practice Question Bank (Chapter 10). Question 1. Which of the following statements is false regarding schizophrenia? * A. A violent episode can be in response to a hallucination. * B. The presence of a major depressive disorder episode can increase the risk of a suicide attempt. * C. Suicide is attempted in up to 50% of patients with schizophrenia. * D. Patients with schizophrenia are more likely to commit a homicide than a member of the general public. Pause. Answer: D. **Why it is correct**: When adequately treated, patients with schizophrenia are no more likely to commit homicide than members of the general public. They are statistically far more likely to be victims of violent crime than perpetrators. **Why the other choices are wrong**: * A: This statement is true because acute unmanaged psychosis or command hallucinations can occasionally trigger agitated or violent behavior. * B: This statement is true because co-occurring major depressive episodes significantly elevate suicide risk, affecting up to 80% of individuals across their lifespan. * C: This statement is true because 20% to 50% of individuals with schizophrenia attempt suicide during their illness, with completed suicide occurring in approximately 5%. Question 2. According to DSM-5-TR criteria, which of the following are characteristic symptoms of schizophrenia? (Select all that apply) * A. Delusions * B. Hallucinations * C. Compulsive behaviors * D. Disorganized speech Pause. Answer: A, B, and D. **Why it is correct**: Criterion A for schizophrenia requires at least two characteristic symptoms present for a significant portion of time during a 1-month period. At least one required symptom must be delusions, hallucinations, or disorganized speech. **Why the other choices are wrong**: * C: Compulsive behaviors are characteristic of obsessive-compulsive disorder (OCD). While OCD can exist as a comorbidity, compulsions are not part of the primary diagnostic criteria for schizophrenia. Question 3. Laura is a 34-year-old woman who was diagnosed with schizophrenia 18 months ago and presents for follow-up. She mentions that she has felt out of it most of the day since her medication change five weeks ago. She also states that she has gained 10 pounds (4.54 kg) since her last visit. This patient is most likely taking: * A. Quetiapine * B. Aripiprazole * C. Risperidone * D. Ziprasidone Pause. Answer: A. **Why it is correct**: **Quetiapine** causes prominent H1 histamine blockade leading to daytime sedation (feeling out of it) and substantial metabolic weight gain. **Why the other choices are wrong**: * B: **Aripiprazole** is a D2 partial agonist associated with low sedation and minimal weight gain. * C: While **risperidone** causes weight gain and prolactin elevation, **quetiapine** is classic for marked daytime sedation and heavy weight gain in board stems. * D: **Ziprasidone** is weight-neutral and must be taken with a 500-calorie meal, making rapid weight gain unlikely. Question 4. Indicate whether each of the following is a positive (P) or negative (N) schizophrenia symptom: 1. Hallucinations 2. Poverty of speech 3. Avoidance of eye contact 4. Disorganized behavior Pause. Answer: 1 is Positive (P), 2 is Negative (N), 3 is Negative (N), 4 is Positive (P). **Why it is correct**: Positive symptoms represent additions or distortions of normal function (hallucinations, disorganized behavior). Negative symptoms represent deficits or subtractions from normal emotional and behavioral functioning (poverty of speech, reduced eye contact). **Why the other choices are wrong**: * 1: Hallucinations add sensory perceptions not present in reality, classifying them as positive symptoms. * 2: Poverty of speech (alogia) reflects a deficit in spontaneous speech production, classifying it as a negative symptom. * 3: Reduced eye contact reflects blunted emotional expression and social withdrawal, classifying it as a negative symptom. * 4: Disorganized behavior adds purposeless or inappropriate motor activity, classifying it as a positive symptom. Question 5. Mrs. Engle is a 75-year-old woman with a 40-year history of type 2 diabetes mellitus who is referred for consultation of new-onset visual hallucinations. She describes seeing pictures of familiar scenes and people, but does not hear voices. She is aware that these images are not real, and during periods of hallucinations she is lucid and alert. She has no cognitive impairment and no past psychiatric history. Her vision has been slowly deteriorating for the past seven years due to macular degeneration. Which of the following is the most likely explanation for this patient? * A. Disorganized schizophrenia * B. Early sign of Alzheimer's disease * C. Charles Bonnet syndrome * D. Temporal lobe epilepsy Pause. Answer: C. **Why it is correct**: Charles Bonnet syndrome occurs in visually impaired elderly individuals (such as those with macular degeneration or diabetic retinopathy) who experience complex visual hallucinations while retaining intact cognition, full alertness, and complete insight that the visions are not real. **Why the other choices are wrong**: * A: Schizophrenia rarely presents after age 60, involves negative symptoms and thought disorder, and lacks the full insight demonstrated here. * B: Early Alzheimer's disease presents primarily with short-term memory deficits and cognitive decline rather than isolated visual hallucinations with preserved cognition. * D: Temporal lobe epilepsy presents with paroxysmal olfactory or gustatory auras or altered consciousness rather than persistent, fully alert visual hallucinations. Question 6. A 22-year-old male diagnosed with paranoid schizophrenia has been taking **haloperidol** for the past six months. During this visit, the PMHNP acknowledges involuntary, repetitive muscle movements and excessive eye blinking that were not documented at his last visit. The appropriate next course of action will be to: * A. Measure serum ALT and AST * B. Measure serum creatinine * C. Administer PHQ-9 questionnaire and compare it to baseline value * D. Administer AIMS questionnaire and compare it to baseline value Pause. Answer: D. **Why it is correct**: Involuntary facial movements and excessive blinking after 6 months of high-potency FGA therapy (**haloperidol**) represent tardive dyskinesia. The Abnormal Involuntary Movement Scale (AIMS) must be administered and compared to baseline to quantify severity. **Why the other choices are wrong**: * A: Liver function tests do not evaluate or quantify extrapyramidal symptoms or tardive dyskinesia. * B: Serum creatinine evaluates renal function and provides no information regarding movement disorders. * C: The PHQ-9 evaluates depressive symptoms rather than medication-induced involuntary movements. Question 7. A 22-year-old patient is newly diagnosed with schizophrenia and is at an outpatient appointment with his parents. Which of the following does the PMHNP realize is the most critical task to complete at this visit? * A. Notify the patient's school or work of the diagnosis * B. Educate the patient on the importance of medication adherence * C. Reassure family members of a low risk of suicide attempt * D. Educate family members of possible increased risk for homicidal tendencies Pause. Answer: B. **Why it is correct**: Psychoeducation emphasizing medication adherence is the single most critical intervention during initial outpatient visits to prevent psychotic relapse, reduce brain tissue loss from recurrent episodes, and lower rehospitalization rates. **Why the other choices are wrong**: * A: Disclosing a diagnosis to an employer or school without explicit patient consent violates HIPAA privacy regulations. * C: Reassuring families of a low suicide risk is dangerously incorrect, as 20% to 50% of patients with schizophrenia attempt suicide. * D: Patients with schizophrenia are not inherently homicidal when receiving care, so framing homicide as a primary concern promotes unnecessary stigma. Question 8. The PMHNP would anticipate that treatment commonly employed to reduce the morbidity of schizophrenia would include all of the following EXCEPT: * A. Psychodynamic psychotherapy * B. Cognitive behavioral therapy * C. Assertive community treatment * D. Social skills training Pause. Answer: A. **Why it is correct**: Psychodynamic psychotherapy is not recommended for schizophrenia, as probing deep unconscious conflicts can increase anxiety and worsen psychotic decompensation. Evidence-based modalities include CBT for psychosis, ACT, and social skills training. **Why the other choices are wrong**: * B: CBT for psychosis is an established evidence-based intervention that helps patients reframe residual delusions and manage distress from hallucinations. * C: Assertive Community Treatment (ACT) provides comprehensive mobile team-based care that reduces hospital readmissions. * D: Social skills training uses behavioral principles to rebuild functional interpersonal and daily living skills. Question 9. A 34-year-old male is brought into the ED with symptoms of muscle rigidity, hyperthermia, and altered mental status. He has been receiving **fluphenazine** for the past three weeks and initiated **lithium** therapy only recently. An expected finding for this patient is: * A. An HbA1c greater than 8.5% * B. Platelets equal to 650,000 / mm3 * C. Serum creatine kinase greater than 1000 IU/L * D. ALT to AST ratio greater than 5 to 1 Pause. Answer: C. **Why it is correct**: The classic triad of muscle rigidity, hyperthermia, and altered consciousness ("hot, stiff, and out of it") in a patient taking **fluphenazine** and **lithium** indicates Neuroleptic Malignant Syndrome (NMS). Elevated serum **creatine kinase (CK)** above 1000 IU/L (often 10,000 to 100,000 IU/L) directly reflects the extent of rhabdomyolysis and severe muscle breakdown. **Why the other choices are wrong**: * A: HbA1c assesses long-term glycemic control and metabolic syndrome, not acute NMS. * B: Platelet count does not reflect muscle necrosis or autonomic crisis in NMS. * D: Transaminase ratios reflect liver pathology rather than the massive skeletal muscle breakdown measured by CK. 🧠 *Next study step*: Review Fitzgerald Chapter 11 (Substance-Related Disorders) to master cross-modality differentials and withdrawal management algorithms. Next. Topic. Clozapine ANC monitoring rules. Bottom Line Summary. * **Clozapine** is indicated for treatment-resistant schizophrenia after failure of at least two adequate trials of different antipsychotics, or for persistent suicidal behavior or severe aggression. * Baseline **Absolute Neutrophil Count** (**ANC**) must be ≥1500/mm³ in the general population, or ≥1000/mm³ for individuals with documented **Benign Ethnic Neutropenia** (**BEN**), before initiating **Clozapine**. * **ANC** monitoring for **Clozapine** requires weekly blood draws for the first 6 months, biweekly draws for months 6 through 12, and monthly draws thereafter if **ANC** remains ≥1500/mm³. * Interrupt **Clozapine** therapy immediately if **ANC** drops below 1000/mm³ due to the risk of life-threatening **agranulocytosis**, which occurs in 1% to 2% of patients. * Tobacco smoke hydrocarbons induce **CYP1A2**, decreasing serum levels of **Clozapine** and **Olanzapine**. Stopping smoking increases drug levels, whereas resuming smoking decreases levels and risks psychotic relapse. * **Clozapine** carries a severe risk of gastrointestinal hypomotility and fatal small bowel obstruction, requiring proactive daily bowel management. * **Long-Acting Injectables** (**LAIs**) are indicated for partial or full medication nonadherence, including **Paliperidone** formulations administered monthly, every 3 months, or every 6 months. Clinical Masterclass: Clozapine, LAIs, and Treatment-Resistance Rules. **First-line** psychopharmacology for schizophrenia consists of second-generation antipsychotics due to equivalent efficacy for positive symptoms and a significantly lower risk of extrapyramidal symptoms and tardive dyskinesia compared to first-generation agents. Clozapine Indications and Treatment Resistance. **Clozapine** is a third-line atypical antipsychotic. It is reserved for treatment-resistant schizophrenia, defined as failure to achieve an adequate clinical response despite at least two full trials of different antipsychotics at proper doses and durations. **Clozapine** is also uniquely FDA-approved to decrease recurrent suicidal behavior and persistent violence or severe aggression in patients with schizophrenia. **Safety alert**: **Agranulocytosis** occurs in 1% to 2% of patients treated with **Clozapine**. This is a sudden, potentially fatal drop in neutrophils that severely compromises immune defense. Clozapine ANC Monitoring Rules. Patient monitoring for neutropenia relies exclusively on the **Absolute Neutrophil Count** (**ANC**). * **General Population Baseline**: **ANC** must be ≥1500/mm³ to start **Clozapine**. * **Benign Ethnic Neutropenia (BEN) Baseline**: **ANC** must be ≥1000/mm³ to start **Clozapine**. * **Monitoring Schedule**: Draw **ANC** weekly for the first 6 months of continuous therapy. If **ANC** remains ≥1500/mm³, draw **ANC** biweekly (every 2 weeks) for months 6 to 12. If **ANC** remains stable after 12 months, draw **ANC** monthly thereafter. * **Interruption Threshold**: Interrupt **Clozapine** treatment immediately if **ANC** falls below 1000/mm³. **Board trap**: While historical centralized **REMS** registry reporting requirements have been streamlined, the mandatory clinical monitoring schedule and strict **ANC** thresholds remain required standard of care. CYP1A2 Drug Interactions and Tobacco Smoke. Hydrocarbons in tobacco smoke are potent inducers of the **CYP1A2** liver enzyme. Both **Clozapine** and **Olanzapine** are primary **CYP1A2** substrates. * Active tobacco smokers require higher doses of **Clozapine** to maintain therapeutic serum levels. * When a patient is admitted to a smoke-free inpatient unit and stops smoking, **CYP1A2** induction disappears, causing **Clozapine** serum levels to double and risking severe toxicity and sedation. * When a patient is discharged and resumes smoking, **CYP1A2** is re-induced, causing **Clozapine** levels to drop significantly and risking psychotic relapse. **Safety alert**: **Clozapine** causes severe anticholinergic gastrointestinal hypomotility, which can lead to severe constipation, fecal impaction, toxic megacolon, and fatal small bowel obstruction. Prescribers must monitor bowel movements regularly and maintain patients on a daily prophylactic bowel regimen such as Miralax or docusate. Long-Acting Injectable Antipsychotics (LAIs). **LAIs** are indicated when patients exhibit partial or full nonadherence to daily oral antipsychotics. * **Paliperidone** is available as a 1-month injection (Invega Sustenna), a 3-month injection (Invega Trinza), and a 6-month injection (Hafyera). * Additional **LAIs** include **Risperidone**, **Haloperidol** decanoate, and **Fluphenazine** decanoate. * **LAIs** maintain consistent therapeutic plasma levels, eliminate daily pill burdens, and substantially reduce relapse and rehospitalization rates. Fitzgerald Sample Test Questions. Question 1. Which of the following statements is false regarding schizophrenia? A. A violent episode can be in response to a hallucination. B. The presence of a major depressive episode can increase the risk of a suicide attempt. C. Suicide is attempted in up to 50% of patients with schizophrenia. D. Patients with schizophrenia are more likely to commit a homicide than a member of the general public. Pause. Answer. D. * **Why It Is Correct**: When treated, individuals with schizophrenia are not more likely to commit homicide than members of the general public. In fact, individuals with schizophrenia are far more likely to be victims of violent crime than perpetrators. * **Why the Other Choices Are Wrong**: * **A**: True statement. Violent outbursts or agitation can occur as a direct response to command hallucinations or severe persecutory delusions. * **B**: True statement. A co-occurring major depressive episode is a major risk factor for suicide in schizophrenia. * **C**: True statement. Up to 20% to 50% of patients with schizophrenia attempt suicide during their lifetime. Question 2. According to DSM-5-TR criteria, which of the following are characteristic symptoms of schizophrenia? (Select all that apply) A. Delusions B. Hallucinations C. Compulsive behaviors D. Disorganized speech Pause. Answer. A, B, and D. * **Why It Is Correct**: Delusions, hallucinations, and disorganized speech represent three of the five core diagnostic domains in DSM-5-TR, and at least one of the active phase symptoms must be one of these three. * **Why the Other Choices Are Wrong**: * **C**: Compulsive behaviors are diagnostic features of obsessive compulsive disorder, not criterion symptoms for schizophrenia. Question 3. Laura, a 34-year-old woman diagnosed with schizophrenia 18 months ago, presents for follow-up. She mentions feeling out of it most of the day since her medication change five weeks ago and has gained 10 pounds (4.54 kg). Which medication is she most likely taking? A. Quetiapine B. Aripiprazole C. Risperidone D. Ziprasidone Pause. Answer. A. * **Why It Is Correct**: **Quetiapine** is a second-generation antipsychotic associated with strong sedation (feeling out of it) due to histamine H1 antagonism, as well as significant metabolic weight gain. * **Why the Other Choices Are Wrong**: * **B**: **Aripiprazole** is a partial dopamine agonist with low sedation and a low risk of weight gain. * **C**: While **Risperidone** causes weight gain, **Quetiapine** is classically tested for prominent daytime sedation combined with metabolic weight gain. * **D**: **Ziprasidone** is largely weight-neutral and requires administration with a 500-calorie meal. Question 4. Indicate whether each of the following is a positive (P) or negative (N) schizophrenia symptom: Hallucinations, Poverty of speech, Avoidance of eye contact, Disorganized behavior. A. Hallucinations: Positive; Poverty of speech: Negative; Avoidance of eye contact: Negative; Disorganized behavior: Positive B. Hallucinations: Negative; Poverty of speech: Positive; Avoidance of eye contact: Positive; Disorganized behavior: Negative C. Hallucinations: Positive; Poverty of speech: Positive; Avoidance of eye contact: Negative; Disorganized behavior: Negative D. Hallucinations: Negative; Poverty of speech: Negative; Avoidance of eye contact: Positive; Disorganized behavior: Positive Pause. Answer. A. * **Why It Is Correct**: Hallucinations and disorganized behavior represent added pathological features (positive symptoms). Poverty of speech (alogia) and poor eye contact represent deficits in normal emotional and social functioning (negative symptoms). * **Why the Other Choices Are Wrong**: * **B**: Inverts positive and negative symptom classifications. * **C**: Incorrectly labels poverty of speech as a positive symptom. * **D**: Incorrectly labels hallucinations as a negative symptom. Question 5. Mrs. Engle, a 75-year-old woman with a 40-year history of type 2 diabetes mellitus, presents with new-onset visual hallucinations of familiar scenes and people. She does not hear voices, remains alert and lucid, has no cognitive impairment, and has no psychiatric history. Her vision has been deteriorating due to macular degeneration. What is the most likely explanation? A. Disorganized schizophrenia B. Early sign of Alzheimer's disease C. Charles Bonnet syndrome D. Temporal lobe epilepsy Pause. Answer. C. * **Why It Is Correct**: Charles Bonnet syndrome occurs in visually impaired elderly individuals (such as those with macular degeneration or diabetic retinopathy) who experience complex visual hallucinations while retaining full alertness, cognitive clarity, and insight that the images are unreal. * **Why the Other Choices Are Wrong**: * **A**: Disorganized schizophrenia presents with formal thought disorder, negative symptoms, and gross functional decline, not isolated visual hallucinations in an alert 75-year-old. * **B**: Alzheimer's disease presents with prominent progressive short-term memory loss and executive dysfunction long before visual hallucinations occur. * **D**: Temporal lobe epilepsy causes brief paroxysmal uncinate fits or olfactory/tactile auras, not sustained, clear visual scenes in a lucid patient. Question 6. A 22-year-old male diagnosed with paranoid schizophrenia has been taking haloperidol for six months. During this visit, the PMHNP observes involuntary, repetitive muscle movements and excessive eye blinking that were not present previously. What is the appropriate next course of action? A. Measure serum ALT and AST B. Measure serum creatinine C. Administer PHQ-9 questionnaire and compare to baseline value D. Administer AIMS questionnaire and compare to baseline value Pause. Answer. D. * **Why It Is Correct**: The Abnormal Involuntary Movement Scale (AIMS) is the standard clinical rating tool used to screen, quantify, and track tardive dyskinesia symptoms such as oro-facial movements and excessive blinking in patients taking antipsychotics. * **Why the Other Choices Are Wrong**: * **A**: Liver transaminases measure hepatic cellular injury, not motor side effects. * **B**: Serum creatinine assesses renal function, which does not evaluate movement disorders. * **C**: The PHQ-9 assesses depressive symptoms, not involuntary motor movements. Question 7. A 22-year-old patient is newly diagnosed with schizophrenia and attends an outpatient appointment with his parents. Which task is most critical for the PMHNP to complete at this visit? A. Notify the patient's school or work of the diagnosis B. Educate the patient on the importance of medication adherence C. Reassure family members of a low risk of suicide attempt D. Educate family members of possible increased risk for homicidal tendencies Pause. Answer. B. * **Why It Is Correct**: Early psychoeducation regarding strict medication adherence is the single most critical intervention to prevent psychotic relapse, disease progression, and rehospitalization. * **Why the Other Choices Are Wrong**: * **A**: Disclosing psychiatric diagnoses to an employer or school without patient authorization violates HIPAA privacy laws. * **C**: Suicide risk in schizophrenia is high, with up to 50% attempting suicide, so reassuring the family of low risk is false and clinically unsafe. * **D**: Medicated patients with schizophrenia do not have an increased risk of homicide compared to the general public. Question 8. The PMHNP anticipates that treatments commonly employed to reduce the morbidity of schizophrenia include all of the following EXCEPT: A. Psychodynamic psychotherapy B. Cognitive behavioral therapy C. Assertive community treatment D. Social skills training Pause. Answer. A. * **Why It Is Correct**: Psychodynamic psychotherapy is not evidence-based for schizophrenia and can exacerbate regression, anxiety, and psychotic distress. * **Why the Other Choices Are Wrong**: * **B**: Cognitive Behavioral Therapy for psychosis (CBTp) is an established evidence-based modality that helps patients manage residual hallucinations and delusions. * **C**: Assertive Community Treatment (ACT) provides multidisciplinary community support that reduces readmissions and improves stability. * **D**: Social skills training helps rebuild interpersonal and daily living competencies. Question 9. A 34-year-old male is brought to the emergency department with muscle rigidity, hyperthermia, and altered mental status. He has been receiving fluphenazine for three weeks and initiated lithium therapy recently. Which lab finding is expected? A. Hemoglobin A1c greater than 8.5% B. Platelets equal to 650,000 C. Serum creatine kinase (CK) greater than 1000 IU/L D. ALT to AST ratio greater than 5 to 1 Pause. Answer. C. * **Why It Is Correct**: Muscular rigidity, hyperthermia, and altered consciousness define Neuroleptic Malignant Syndrome (NMS). Rhabdomyolysis caused by severe muscle breakdown leads to dramatic elevations in serum creatine kinase (CK), often exceeding 1000 IU/L. * **Why the Other Choices Are Wrong**: * **A**: Elevated HbA1c indicates diabetes or metabolic syndrome, not acute muscle necrosis. * **B**: Elevated platelets indicate thrombocytosis, which is not a diagnostic marker for NMS. * **D**: Transaminase ratios assess liver pathology, not skeletal muscle breakdown. 💡 **Next Study Step**: Proceed to **FITZGERALD CH11 — Substance-Related Disorders** to master **CYP450** interactions, intoxication and withdrawal toxidromes, and pharmacological management of addiction. Next. Topic. Clozapine safety and side effects. FITZGERALD CH10: Schizophrenia - Clozapine Safety and Side Effects. Bottom Line Summary. - **First-line** second-generation antipsychotics (SGAs) are preferred for schizophrenia, but **clozapine** is the gold-standard third-line agent for treatment-resistant schizophrenia, persistent suicide risk, or refractory aggression. - **Absolute Neutrophil Count (ANC)** must be greater than or equal to 1,500/mm³ before initiating clozapine therapy. - **ANC Monitoring Schedule**: Baseline ANC, followed by weekly ANC draws for the first 6 months, every 2 weeks for months 6 to 12, and monthly thereafter if ANC remains at or above 1,500/mm³. - Interrupt and hold clozapine immediately if the ANC drops below 1,000/mm³ to prevent life-threatening agranulocytosis. - **Myocarditis risk** peaks during the first 6 weeks of clozapine therapy; monitor CRP, troponins, and cardiac symptoms closely if chest pain or shortness of breath occurs. - **Gastrointestinal hypomotility and paralytic ileus** cause severe bowel obstruction; initiate a proactive bowel regimen such as Miralax at treatment onset. - Polycyclic aromatic hydrocarbons in tobacco smoke induce the **CYP1A2** enzyme; smoking cessation increases clozapine blood levels toward toxicity, whereas resuming smoking decreases drug levels. - Dose-dependent **seizure risk** increases sharply at higher doses, alongside profound sedation, orthostatic hypotension, nocturnal sialorrhea, and severe weight gain. High-Yield Clinical Teaching and Concept Synthesis. Indications and Line of Therapy. - **First-line**: Second-generation antipsychotics like risperidone, olanzapine, or aripiprazole are first-line for schizophrenia due to lower extrapyramidal side effect (EPS) risk. - **Clozapine indication**: Indicated after failure of at least two adequate trials of different antipsychotics. It is uniquely indicated for reducing suicide risk in schizophrenia and controlling refractory violent or aggressive behavior. - **Board trap**: Do not start clozapine as first-line therapy for uncomplicated acute psychosis. Boards test clozapine as a third-line intervention reserved for treatment resistance or severe suicidality. Hematologic Safety and ANC Rules. - **Safety alert**: Agranulocytosis occurs in 1% to 2% of patients taking clozapine and can lead to fatal sepsis. - **ANC threshold**: Baseline ANC must be at least 1,500/mm³ (or 1,000/mm³ for confirmed benign ethnic neutropenia). - **Monitoring frequency**: 1. Months 1 to 6: Draw ANC weekly. 2. Months 7 to 12: Draw ANC every 2 weeks. 3. Month 12 onward: Draw ANC monthly for the duration of treatment. - **Action threshold**: If ANC falls below 1,000/mm³, hold clozapine immediately, obtain hematology consultation, and monitor daily for signs of infection. Cardiovascular and Neurologic Red Flags. - **Safety alert**: Clozapine carries a black box warning for fatal myocarditis and cardiomyopathy. The peak window for myocarditis is the first 6 weeks. Any fever, chest pain, dyspnea, tachycardia, or palpitations during initial titration requires immediate ECG, troponin, and CRP labs. - **Seizure risk**: Clozapine lowers the seizure threshold in a dose-dependent fashion. At doses exceeding 300 to 600 mg daily, seizure risk rises sharply. - **Orthostatic hypotension**: Severe orthostasis, bradycardia, and syncope can occur during rapid titration. Slow, gradual dose escalation is mandatory. Gastrointestinal and Metabolic Complications. - **Safety alert**: Clozapine-induced gastrointestinal hypomotility can progress to paralytic ileus, bowel ischemia, small bowel obstruction, and death. Constipation must be managed proactively with daily stool softeners or osmotic laxatives like Miralax. - **Sialorrhea**: Nocturnal drooling is extremely common due to complex muscarinic actions. Treat with sublingual ipratropium spray or atropine 1% ophthalmic drops administered orally under the tongue. - **Metabolic syndrome**: Clozapine and olanzapine carry the highest risk for marked weight gain, severe dyslipidemia, and new-onset type 2 diabetes. Baseline and routine monitoring of BMI, fasting plasma glucose, and lipid panels is required. Drug Interactions and CYP1A2 Smoking Effects. - **Board trap**: Tobacco smoke contains polycyclic aromatic hydrocarbons that act as potent inducers of the **CYP1A2** enzyme, which metabolizes clozapine. - When a patient who smokes heavily is admitted to a smoke-free inpatient unit, CYP1A2 induction stops. Clozapine levels rise, risking toxicity, extreme sedation, and seizures. - When discharged, if the patient resumes heavy smoking, CYP1A2 is induced again. Clozapine levels fall rapidly, risking loss of efficacy and psychotic relapse. Board-Style Practice Questions. Question 1. A 34-year-old male with a 10-year history of treatment-resistant schizophrenia is brought to the emergency department experiencing severe muscle rigidity, high fever of 103.2 degrees Fahrenheit, diaphoresis, fluctuating blood pressure, and altered mental status. He was recently started on a combination of trifluoperazine and lithium therapy. Which laboratory finding is most expected in this patient? A) Glycated hemoglobin (HbA1c) greater than 8.5 percent B) Platelet count of 650,000/mm³ C) Serum creatine kinase (CK) greater than 1,000 IU/L D) ALT to AST ratio greater than 5 to 1 Pause. Answer. **Best Answer:** C **Quick Answer:** The patient presents with Neuroleptic Malignant Syndrome (NMS), characterized by massive serum creatine kinase elevation resulting from severe muscle breakdown. **Key Clue:** High fever, severe muscle rigidity, autonomic instability, and altered mental status ("hot, stiff, and out of it"). **Why It Is Correct:** NMS is a life-threatening medical emergency caused by dopamine blockade. Severe rhabdomyolysis causes serum CK levels to rise dramatically, often between 1,000 and 100,000 IU/L, creating a risk for acute renal failure and myoglobinuria. **Why the Other Choices Are Wrong:** - **A:** HbA1c assesses long-term glycemic control and metabolic syndrome, not acute rhabdomyolysis in NMS. - **B:** Thrombocytosis is not a characteristic diagnostic marker of NMS. - **D:** Transaminase ratios evaluate hepatic injury, whereas NMS directly causes skeletal muscle necrosis marked by CK elevation. **Test-Taking Pearl:** Remember NMS as "hot, stiff, and out of it." The hallmark lab finding on board exams is a sky-high serum creatine kinase (CK). Question 2. A 22-year-old male diagnosed with paranoid schizophrenia has taken haloperidol for six months. During a routine outpatient follow-up, the PMHNP observes involuntary facial grimacing, lip smacking, and excessive eye blinking that were not present on prior visits. What is the most appropriate next step in management? A) Order serum liver function tests (ALT and AST) B) Order serum creatinine and blood urea nitrogen C) Administer the PHQ-9 questionnaire and compare to baseline D) Administer the Abnormal Involuntary Movement Scale (AIMS) and compare to baseline Pause. Answer. **Best Answer:** D **Quick Answer:** The PMHNP must objectively quantify suspected tardive dyskinesia using the AIMS tool before adjusting antipsychotic therapy. **Key Clue:** Involuntary, repetitive muscle movements involving facial grimacing, lip smacking, and eye blinking after six months of first-generation antipsychotic use. **Why It Is Correct:** The AIMS is the standardized clinician-administered tool used to detect, track, and monitor tardive dyskinesia in patients receiving antipsychotic medications. **Why the Other Choices Are Wrong:** - **A:** Liver function tests evaluate hepatic toxicity, not neurological extrapyramidal movement disorders. - **B:** Renal function tests do not assess or diagnose antipsychotic-induced movement pathology. - **C:** The PHQ-9 measures depressive symptom severity rather than involuntary motor movements. **Test-Taking Pearl:** When a patient on an antipsychotic develops lip smacking or involuntary facial movements, the immediate best next step is to perform an AIMS assessment. Question 3. A 22-year-old male is newly diagnosed with schizophrenia and presents for an outpatient follow-up accompanied by his parents. Which clinical task is most critical for the PMHNP to complete during this visit? A) Notify the patient's employer or school regarding the new psychiatric diagnosis B) Educate the patient and family on the critical importance of medication adherence C) Reassure the family members that the patient carries a very low risk of suicide D) Educate family members that the patient has a significantly heightened risk for homicidal violence Pause. Answer. **Best Answer:** B **Quick Answer:** Enhancing medication adherence early in the disease course is the single most vital intervention to prevent relapse, rehospitalization, and functional decline. **Key Clue:** Newly diagnosed schizophrenia presenting in the outpatient setting. **Why It Is Correct:** Non-adherence is the primary driver of psychotic relapse and clinical deterioration. Educating the patient and family on strict adherence reduces two-year relapse rates from over 70 percent down to under 30 percent. **Why the Other Choices Are Wrong:** - **A:** Disclosing diagnostic information to an employer or school without explicit patient consent violates HIPAA privacy regulations. - **C:** Patients with schizophrenia have a high suicide risk, with 20 to 50 percent attempting suicide and 5 percent completing suicide. Reassuring them of low risk is false and unsafe. - **D:** When treated with medication, individuals with schizophrenia are no more likely to commit homicide than the general public. **Test-Taking Pearl:** In early schizophrenia management, medication adherence is always a top clinical priority to halt disease progression and neurostructural deterioration. Question 4. A 34-year-old woman with schizophrenia presents for follow-up five weeks after a medication adjustment. She reports feeling excessively drowsy throughout the day and has gained 10 pounds since her last visit. Which medication was most likely initiated? A) Quetiapine B) Aripiprazole C) Ziprasidone D) Haloperidol Pause. Answer. **Best Answer:** A **Quick Answer:** Quetiapine is a second-generation antipsychotic known for pronounced H1 histamine blockade causing marked sedation and significant weight gain. **Key Clue:** Excessive drowsiness ("out of it") combined with 10 pounds of rapid weight gain following a recent medication change. **Why It Is Correct:** Quetiapine and olanzapine produce high levels of sedation and metabolic weight gain among second-generation agents. Risperidone also carries moderate weight gain, but quetiapine's strong antihistaminic properties produce classic daytime somnolence. **Why the Other Choices Are Wrong:** - **B:** Aripiprazole is a partial D2 agonist with minimal H1 affinity, making it weight-neutral and activating rather than sedating. - **C:** Ziprasidone is largely weight-neutral and requires administration with a 500-calorie meal for absorption. - **D:** Haloperidol is a high-potency first-generation agent associated with high EPS risk rather than primary metabolic weight gain. **Test-Taking Pearl:** Quetiapine, olanzapine, and clozapine are the heavy hitters for sedation and weight gain on board exams. 💡 **Next Study Step:** Review **Fitzgerald Chapter 11: Substance-Related Disorders** to master CYP450 inducer/inhibitor interactions, alcohol withdrawal protocols, and dual-diagnosis management in psychotic disorders. Next. End of this drive.